MedTrace Logo

Trial of RNActive®-Derived Cancer Vaccine and Local Radiation in in Stage IV Non Small Cell Lung Cancer (NSCLC)

NCT01915524 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2016-08-05

No results posted yet for this study

Summary

The purpose of this study is to determine whether the new RNActive derived lung cancer vaccine CV9202 in combination with local radiation therapy is safe, tolerable and immunogenic for the consolidation and maintenance treatment of stage IV non small cell lung cancer (NSCLC) after first-line chemotherapy or therapy with an EGFR tyrosine kinase inhibitor.

Conditions

  • Non-Small Cell Lung Carcinoma

Interventions

BIOLOGICAL

CV9202

Intradermal injection of CV9202

RADIATION

local radiation

Radiotherapy will be administered in 4 daily fractions of 5 GY each to be administered within one week

Sponsors & Collaborators

  • CureVac

    lead INDUSTRY

Principal Investigators

  • Alfred Zippelius, Prof. Dr. · University Hospital Basel, Clinic for Medical Oncology

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • Austria
  • Germany
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01915524 on ClinicalTrials.gov